Search Details

Word: arvs (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...pricing of antiretroviral (ARV) treatments for AIDS and HIV is a particularly contentious issue. Drug companies say they need to recoup the billions of dollars spent on research, and argue that generic copies eliminate the rewards that fund drug discovery and development. (Drug patents typically expire after 20 years in the U.S., but that figure varies from country to country.) Some aid groups and scientists say the drugs' prices put them beyond the reach of those who need them most, and claim the companies put profits and patents before lives...

Author: /time Magazine | Title: The Halo Effect | 9/20/2007 | See Source »

...said that although the government was pleased with the low rate of infection, it recognized the price tag that comes with increased life expectancy of those using antiretrovirals. “We need to take some strategic and political decisions as a way to reduce the financial charges [of ARV drugs]. These measures will depend on the Brazilian mobilizations and the international community,” he said...

Author: By Jessica A. Estep, CRIMSON STAFF WRITER | Title: Univ. Helps Brazil Slow AIDS Rates | 3/23/2007 | See Source »

...successfully bound to a healthy cell; called an entry inhibitor, it blocks the virus from entering the cell and integrating its viral genetic material into the host cell's genome. In a study of more than 1000 patients who had developed resistance to at least three of the four ARV classes, twice the number of patients given maraviroc versus those taking placebo enjoyed undetectable levels of virus after eight months. The results were enough to convince Pfizer to apply for approval to the Food and Drug Administration, which will begin its review next month. If approved, maraviroc would...

Author: /time Magazine | Title: Beefing Up the Arsenal Against AIDS | 3/2/2007 | See Source »

...this good news on the ARV front, however, is in stark contrast to the slower progress being made on an AIDS vaccine. "What we're seeing now with ARVs is the result of investments that were made 10 years ago," says Dr. Seth Berkley, president and CEO of the International AIDS Vaccine Initiative, a leading HIV vaccine developer. "Funding for vaccine research has always fallen far short of that devoted to drug development, and for a period, there was very little happening in the vaccine field. Had there been a sustained vaccine effort simultaneous with the drug effort, we probably...

Author: /time Magazine | Title: Beefing Up the Arsenal Against AIDS | 3/2/2007 | See Source »

...intents and purposes, keep them alive long enough for them to date, attend college, marry, and start families of their own. They are indeed fortunate - although living with HIV, even in the U.S., remains a challenge. But these young pioneers - many of them among the first to test antiretroviral (ARV) medications against HIV - are teaching doctors valuable lessons about how best to treat young patients affected by the disease. Their lessons, learned the hard way through painful trial and error, will spare millions of children in the developing world from treading the same difficult path...

Author: /time Magazine | Title: Learning from the Living | 12/1/2006 | See Source »

Previous | 1 | 2 | 3 | 4 | 5 | Next